Stock In Spotlight: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)


Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) closed its last session at $2.42. The stock traded within a range of $2.28 and $2.43. The company operates in the Healthcare sector with a market capitalization of 668160. Trading volume for Synergy Pharmaceuticals, Inc. was 6.83 Million in its previous trading session. Currently, Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) has an average volume of 7.19 Million.

Company Profile

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.

Analyst Views

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) received a Buy rating from 3 analysts. 0 analysts gave its stock an Outperform rating. 1 analysts say it’s a Hold while 0 analysts provided their expert opinion as Sell.

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) touched its 1-Year High price of $7.15 on 01/31/17 and its 1-Year Low price of $1.68 on 11/15/17.

EPS & Financials

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) reported its EPS in the last quarter as $-0.22/Share beating the analyst estimate of $-0.28/Share by a difference of $0.06. This showed a surprise of 21.4% in the last quarter earnings.

For the current quarter, 6 analysts are projecting a mean EPS of $-0.19/share. According to their observations and findings, the stock could provide a high EPS of $-0.18/share and a low EPS of $-0.21/share.

Analysts believe that the company has the potential to earn average revenue of $7.3 Million for the current quarter. According to their predictions high & low revenue estimates are 9.39 Million and 5 Million respectively.

Technical Analysis

By taking a look at the stock’s current statistics it can gauged that the stock candle is BULLISH with MEDIUM volatility. Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) has a 20-Day average volume of 6.61 Million. According to today’s trading volume Synergy Pharmaceuticals, Inc. is BELOW its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days.

Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The trend for the past 10-days shows that the company was in BEARISH territory while an analysis of the last 40-Day trend shows a BEARISH signal. The 100-Day trend also shows a BEARISH trend as well.

The company currently has an insider ownership of 0.78 Percent and Institutional ownership of 62.2 Percent. The return on assets stands at -195.9%, Return on Equity currently is -540.2% and the Return on Investment value is 0%.

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) gross margin percentage stands at 7.6% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent. The stock is currently moving above its 20-Day Simple Moving Average of 9.7% with a 50-Day Simple Moving Average of 8.31 percent. As of today, the company has a SMA200 (200-day simple moving average) of -27.37 Percent. The Stock has YTD (year to date) performance of 8.52 percent.

The TTM operating margin for the company stands at 0%. The return on invested capital is at 0%, which is good, compared to its peers. The Free Cash Flow or FCF margin is 0.

The company’s stock is currently moving with a -ve distance from the 200 day SMA of approximately -27.37%, and has a solid year to date (YTD) performance of 8.52% which means that the stock is constantly adding to its value from the previous fiscal year end price.